Literature DB >> 11893857

Comparison of IgE antibody concentrations to pyromellitic dianhydride-modified laminin and human serum albumin in sera of exposed workers with respiratory complaints.

A B Czuppon1, R Merget, M Raulf-Heimsoth, T Bruening.   

Abstract

BACKGROUND: Acid anhydrides are used in a variety of industrial branches because of their highly reactive anhydride groups. Adverse effects of anhydride exposure include toxic/irritative effects as well as IgE- and IgG-mediated respiratory disorders. It was the aim of this study to examine the usefulness of conjugates of pyromellitic dianhydride (PMDA) and laminin, a respiratory tract protein, for the in vitro diagnosis of sensitization to PMDA.
METHODS: Sera of PMDA-exposed workers (n = 9) and nonexposed controls (n = 8) were tested with an enzyme allergosorbent test (EAST). Human laminin and human serum albumin (HSA) were derivatized with PMDA and used as solid-phase in a commercial assay.
RESULTS: Seven out of 9 exposed workers revealed elevated IgE antibody concentrations (>0.35 kU/l) against laminin-PMDA whereas 5 of 9 subjects had elevated IgE antibody concentrations to HSA-PMDA. All 9 workers had elevated IgE antibody concentrations in at least one of the two tests. Of the 4 workers who complained of shortness of breath, 3 were positive for laminin-PMDA and 2 for HSA-PMDA. All of the nonexposed subjects were negative (<0.35 kU/l) for laminin-PMDA.
CONCLUSION: PMDA-modified laminin could provide an additional diagnostic tool for the detection of sensitization to PMDA.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11893857     DOI: 10.1159/000048172

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  1 in total

1.  Pyromellitic dianhydride (PMDA) may cause occupational asthma.

Authors:  Milene Torp Madsen; Lars Rauff Skadhauge; Anders Daldorph Nielsen; Jesper Baelum; David Lee Sherson
Journal:  Occup Environ Med       Date:  2019-01-11       Impact factor: 4.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.